Advancing precision drug through innovative chemistry and advanced molecular technologies.
Integrated CDMO services spanning discovery, process development, custom synthesis and commercial manufacturing.
Delivering reliable CDMO solutions for innovative therapeutics worldwide.
CHEMOS致力于打造以产品为牵引、合成技术驱动的CDMO品牌，为全球制药及生物技术公司提供有机合成、工艺开发、定制合成和项目放大服务。我们聚焦于药物递送系统（LNP、GalNAc）、生物偶联化学（ADC Linker）、放射性药物化学（DOTA、NOTA）、靶向蛋白降解（PROTAC、分子胶）及功能性分子砌块等高壁垒领域，依托研发团队、先进合成技术、分析平台和生产基地，为客户提供从路线开发到放大生产支持的系统化解决方案。
了解我们最新发展与行业洞察
Chongqing Xingcan Pharmaceutical Technology Co., Ltd. (CHEMOS) will participate in CPHI China 2026, held on 16–18 June 2026 at SNIEC, Shanghai (Booth No.: W9C42). The company will showcase its small molecule CDMO services, advanced drug delivery materials (lipids, PEG derivatives, linkers, functional excipients, etc.), and process development & manufacturing capabilities. CHEMOS warmly welcomes global partners, clients, and industry professionals to discuss custom synthesis, CDMO cooperation, material sourcing, scale-up manufacturing, and long-term strategic partnerships.
更多Trifluoromethanesulfonic anhydride (Tf2O) is a highly efficient electrophilic activator in modern pharmaceutical synthesis, enabling precise introduction of fluorine atoms or trifluoromethyl groups into molecular scaffolds. This enhances metabolic stability, lipophilicity, and biological activity—key parameters in drug discovery. Its mechanism involves converting alcohols into reactive triflates, facilitating nucleophilic substitutions and cross-couplings. As a professional CDMO, we offer custom synthesis of Tf2O at ≥99% purity, scalable from gram to kilogram and beyond, with stringent quality control and fast delivery. Our services help pharmaceutical companies streamline fluorination steps, shorten synthetic routes, reduce costs, and accelerate the transition from lab to commercialization for novel fluorinated APIs.
更多
Antibody-drug conjugates (ADCs) enable targeted cancer therapy by linking antibodies to cytotoxic drugs, realizing Paul Ehrlich’s “magic bullet.” A recent review highlights linkers as key to stability and efficacy: cleavable linkers (e.g., enzyme-sensitive Val-Cit) enable precise tumor release, while non-cleavable linkers offer better plasma stability. Core strategies include site-specific conjugation, release triggers, and hydrophilic spacers to prevent aggregation. Advances feature dual-stimuli triggers, traceless release, branched structures, and AI tools like Linker-GPT. With 17 ADCs approved, challenges remain in immunogenicity, manufacturing, and resistance; future efforts focus on computational modeling and nanotechnology to expand applications beyond oncology.
无论您处于早期研发、路线探索、工艺开发还是项目放大阶段，CHEMOS始终以有机合成能力、研发团队和生产基地为支撑，为您提供高效、可靠的定制合成解决方案。
